Featured Oncology NewsFDA Approves Celltrion and Teva's Trastuzumab Biosimilar, Herzuma
December 17, 2018
Peer-Spectives is a new podcast series that is moderated by our editor-in-chief Robert Figlin, MD, and
features select thought-leaders covering the latest clinical developments in a wide range of cancer settings.
Moderated by:
Steven Spielberg Family
Chair in Hematology-Oncology
Cedars-Sinai Medical Center
We explore the scope of the escalating cost of cancer care, discuss the factors that contribute to the total cost of cancer care,
and provide resources to help us all understand the facts regarding the cost of cancer care.
Sponsored by:
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.
Merck Raised Prices Five Drugs Including Keytruda In November
Prominent Doctors Aren’t Disclosing Their Industry Ties in Medical Journal Studies. And Journals Are Doing Little to Enforce Their Rules
First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type
Pipeline Online is the most comprehensive and up to date oncology pipeline information resource that is widely available on the web ...
OBR Finance tracks the market performance of oncology companies and products, and compares our performance versus other indices ...
OBR Radar is a snapshot of upcoming pivotal events in the oncology industry such as FDA action dates, anticipated announcement of pivotal clinical data, and ODAC dates ...
Houston, Texas
San Francisco, CA
San Francisco, CA
Amsterdam, The Netherlands
Santa Monica, CA
Washington, DC
Orlando, FL
Atlanta, GA
Orlando, FL
Geneva, Switzerland
Denver, CO
Chicago, IL
RAI Amsterdam, The Netherlands
Lugano, Switzerland
San Francisco, CA
Buenos Aires, Argentina
Orlando, FL
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.
Featured Content
Previous
News Story Commentary
Meet the Editorial BoardView all Commentary
Second-Line Nivolumab Is Not Superior to Chemotherap...
December 14th 2018 by H. Jack West, MD
Though the authors and proponents from BMS highlight that the handful of patients who responded to ...
Read More
Imfinzi Demonstrates Clinical Activity In Stage IV, ...
December 14th 2018 by H. Jack West, MD
These data on MYSTIC stave off the executioner for durva or durva/treme in first line treatment of ...
Read More
Loxo and Bayer's Amazing Drug Has An Expensive Price
December 14th 2018 by Thomas Marsland, MD
Sorry to all my Pharma buddies but it is rare when I get excited when a detail rep come to visit. T...
Read More
Surgery May Benefit Some With Early Prostate Cancer:...
December 13th 2018 by Tomasz M. Beer, MD, FACP
This is a long term outcome report of an older study. It confirms the previous findings of a benef...
Read More
Whole Body PET/MRI Provides One-Stop-Shop for Stagin...
December 12th 2018 by Tomasz M. Beer, MD, FACP
Performance equal to nomograms is certainly encouraging, but what is needed is performance that is ...
Read More
Non-Invasive MRI Scan For Prostate Cancer Recommende...
December 12th 2018 by Tomasz M. Beer, MD, FACP
MRI imaging prior to prostate biopsy is emerging as a strategy to reduce unproductive biopsies and ...
Read More
OBR Green